## Clinical Scenario Analysis The patient initially presented with **stable exertional angina** (predictable, reproducible, relieved by rest). After 2 weeks of continuous isosorbide mononitrate monotherapy, the angina has become **unpredictable and occurs at rest and night** — a cardinal sign of **nitrate tolerance**. ## Nitrate Tolerance: Mechanism & Recognition **Key Point:** Continuous exposure to organic nitrates (without a nitrate-free interval) leads to loss of bioavailability of nitric oxide (NO), resulting in loss of vasodilatory effect despite ongoing drug administration. ### Pathophysiology 1. Organic nitrates require enzymatic bioconversion to NO by mitochondrial aldehyde dehydrogenase (ALDH-2) 2. Continuous nitrate exposure depletes ALDH-2 cofactor (tetrahydrofolate) and generates superoxide, which scavenges NO 3. Result: **Pseudo-tolerance** — the drug is present but ineffective ### Clinical Features of Tolerance - Loss of antianginal effect despite adequate dosing - Return of angina (often more frequent, severe, and unpredictable) - Angina may shift from exertional to rest/nocturnal pattern - Occurs within **24–72 hours** of continuous nitrate exposure ## Prevention & Management **High-Yield:** The gold standard prevention is **nitrate-free interval (NFI)** of ≥10–12 hours daily. | Strategy | Example | Efficacy | |----------|---------|----------| | Once-daily dosing with 12-h NFI | Isosorbide mononitrate 60 mg 8 AM (covers day) | Prevents tolerance | | Twice-daily with 12-h gap | ISMN 20 mg at 8 AM and 2 PM | Prevents tolerance | | Continuous dosing without NFI | ISMN 60 mg daily, no gap | **Tolerance develops** | **Clinical Pearl:** The patient was prescribed a once-daily long-acting nitrate without a nitrate-free interval, which is a common prescribing error. The solution is to introduce a 12-hour nitrate-free window (e.g., give the dose in the morning only, leaving the night free). ### Why Other Options Are Incorrect **Option 1 (Progression to unstable angina):** While the symptom pattern resembles unstable angina, the **temporal relationship to continuous nitrate initiation** and the **predictable response to nitrate-free interval** make tolerance the diagnosis. Unstable angina would not resolve simply by adjusting nitrate timing. **Option 2 (Amlodipine-induced vasospasm):** Amlodipine is a dihydropyridine calcium channel blocker — it causes **vasodilation**, not vasospasm. Vasospasm is associated with non-dihydropyridines (verapamil, diltiazem) in some patients, and amlodipine was already on board before the change in symptoms. **Option 3 (Inadequate beta-blocker therapy):** The patient is not on a beta-blocker. While beta-blockers are indicated in stable angina, their absence does not explain the **acute change in symptom pattern** after nitrate initiation. The HR is 88/min (reasonable), and the symptom shift is directly temporally linked to nitrate dosing, not beta-blocker absence. ## Management of This Patient 1. **Introduce nitrate-free interval:** Change ISMN 60 mg once daily to ISMN 20 mg at 8 AM and 2 PM (with 12-h gap overnight), OR give 60 mg at 8 AM only 2. **Add beta-blocker:** Metoprolol 50 mg BD or atenolol 50 mg daily (indicated for stable angina, reduces myocardial O₂ demand) 3. **Continue aspirin and statin** (already on amlodipine for BP control) 4. **Reassess in 1–2 weeks** — tolerance should resolve with NFI **Mnemonic: NITRATE TOLERANCE = NFI (No Free Interval)** — Remember that continuous nitrate use without a nitrate-free interval is the cause of tolerance.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.